In a study by Zhao et al. [18], it was shown that SARS patients that were randomly receiving INF-α exhibited the shortest admission length, and a relatively short time for improvement of dyspnea and the clearing of chest X‐ray films when compared to those under different treatment regimens. The gene discussed is IFNA17; the disease is severe acute respiratory syndrome.